Martin  Babler net worth and biography

Martin Babler Biography and Net Worth

Martin Babler serves as Director of the Company. Mr. Babler has served as Chief Executive Officer at Principia Biopharma Inc., a biopharmaceutical company. From December 2007 to April 2011, Mr. Babler served as President and Chief Executive Officer of Talima Therapeutics, Inc., a pharmaceutical company. From 1998 to 2007, Mr. Babler held several positions at Genentech, Inc., a biopharmaceutical company, most notably as Vice President, Immunology Sales and Marketing. While at Genentech he also helped to build and led the Commercial Development organization and led the Cardiovascular Marketing organization. Mr. Babler was previously employed at Eli Lilly and Company, a pharmaceutical company, in positions focused on sales, sales management, global marketing and business development. Mr. Babler presently serves on the board of directors of Principia Biopharma and on the Emerging Companies Section and the Health Section Governing Boards of the Biotechnology Innovation Organization, or BIO. Mr. Babler received a Swiss Federal Diploma in pharmacy from the Federal Institute of Technology in Zurich and completed the Executive Development Program at the Kellogg Graduate School of Management at Northwestern University.

How old is Martin Babler?

Mr. Babler is currently 54 years old. There are 4 older executives and no younger executives at Principia Biopharma. Learn More on Martin Babler's age.

How do I contact Martin Babler?

The corporate mailing address for Mr. Babler and other Principia Biopharma executives is 220 East Grand Avenue, SOUTH SAN FRANCISCO CA, 94080. Principia Biopharma can also be reached via phone at 650-416-7700 and via email at [email protected]. Learn More on Martin Babler's contact information.

Has Martin Babler been buying or selling shares of Principia Biopharma?

Martin Babler has not been actively trading shares of Principia Biopharma over the course of the past ninety days. Most recently, Martin Babler sold 15,000 shares of the business's stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $61.86, for a transaction totalling $927,900.00. Learn More on Martin Babler's trading history.

Who are Principia Biopharma's active insiders?

Principia Biopharma's insider roster includes Martin Babler (CEO), Alan Colowick (Director), and Dolca Thomas (Insider). Learn More on Principia Biopharma's active insiders.

Martin Babler Insider Trading History at Principia Biopharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/23/2020Sell15,000$61.86$927,900.00View SEC Filing Icon  
3/3/2020Sell15,000$63.47$952,050.00View SEC Filing Icon  
12/17/2019Sell25,000$52.96$1,324,000.00View SEC Filing Icon  
See Full Table

Martin Babler Buying and Selling Activity at Principia Biopharma

This chart shows Martin Babler's buying and selling at Principia Biopharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Principia Biopharma Company Overview

Principia Biopharma logo
Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $100.05
Low: $100.05
High: $100.05

50 Day Range

MA: $100.05
Low: $99.95
High: $100.27

2 Week Range

Now: $100.05
Low: $25.35
High: $101.89

Volume

N/A

Average Volume

729,676 shs

Market Capitalization

$3.32 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86